Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 5/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22973161 | 0.92 | KRAS (0.55) | KRASCRBNP2RY12 | |
| SCHEMBL22973193 | 0.89 | KRAS (0.54) | KRASCRBNTLR7P2RY12MERTK | |
| SCHEMBL21458517 | 0.86 | KRAS (0.67) | KRASCRBNTLR9ACHESLC2A1 | |
| SCHEMBL30244610 | 0.85 | KRAS (0.68) | KRASCRBNTLR9ACHECNR1 | |
| SCHEMBL21458892 | 0.84 | KRAS (0.59) | KRASCRBNCNR1CNR2P2RY12 | |
| SCHEMBL21458484 | 0.83 | KRAS (0.51) | KRASTLR9ACHECNR1CNR2 | |
| SCHEMBL21458735 | 0.83 | KRAS (0.68) | KRASCRBNTLR9ACHESLC2A1 | |
| SCHEMBL21458368 | 0.82 | KRAS (0.80) | KRASCRBNTLR9ACHECNR1 | |
| SCHEMBL22324758 | 0.82 | KRAS (0.48) | KRASCRBNTLR9CNR1CNR2 | |
| SCHEMBL30213358 | 0.82 | KRAS (0.48) | KRASCRBNTLR9CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3774777-A2 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112218859-A | Modulators of proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KRAS 242/4885CRBN 2/4885TLR9 4850/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KRAS 242/4885CRBN 2/4885TLR9 4850/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | KRAS 289/4885CRBN 1/4885TLR9 4697/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | KRAS 242/4885CRBN 2/4885TLR9 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.